 MyoKardia, Inc. MYOK today announced the presentation and publication of positive data from the companys Phase 2a clinical trial of danicamtiv formerly MYK-491 along with nonclinical data elucidating danicamtivs novel mechanism of action. Results from both the clinical and nonclinical studies of danicamtiv were featured at the European Society of Cardiologys Heart Failure Association HFA Discoveries online event and published simultaneously in the European Journal of Heart Failure. 